Anemia Clinical Trial
Official title:
A Randomized Control Trial of the Lucky Iron Fish to Improve Hemoglobin Concentration in Women in Preah Vihear, Cambodia
The purpose of this research is to determine if cooking with an iron ingot called the Lucky Iron Fish (LIF) increases the hemoglobin status in women of childbearing age living in Preah Vihear, Cambodia. The investigators hypothesize that the use of the LIF during cooking over a 12-month period will be as efficacious at increasing hemoglobin concentration as iron supplements (18 mg elemental iron) and will be more efficacious than the control.
Background: Anemia is prevalent in Cambodia, affecting ~44% of women. The causes of anemia
are multifactorial. Globally, the most common form is iron deficiency anemia (IDA), which can
lead to adverse perinatal health outcomes. In Cambodia, there is evidence that suggests
hemoglobinopathies (genetic hemoglobin [Hb] disorders) are prevalent (~50%) and are a major
contributor to anemia. In Preah Vihear province, Cambodia, the estimated prevalence of
malaria is ~12.3%. Malaria contributes to anemia through a decrease in the production of red
blood cells, and an increased destruction of red blood cells.
In Cambodia, iron supplements are recommended to treat anemia, however there is evidence of
low compliance among women. The use of cast iron pots has proven to be an effective
alternative to prevent and reduce IDA in developing countries. However, cast iron pots are
not commonly used in Cambodia because they are expensive, difficult to clean, and heavy. A
novel alternative is the Lucky Iron Fish (LIF), which is an iron ingot used during cooking as
an in-home fortification system of iron transfer. The LIF ingot is small, lightweight, and
easy to clean. Previous research in Cambodia confirmed the acceptance of the LIF to be high,
but findings from this study were inconclusive and had several limitations.
Objective: The primary objective of this study is to determine the efficacy of the LIF to
increase Hb concentration in Cambodian women of reproductive age.
Methods: A total of 330 women (18-49 y) with mild or moderate anemia (Hb 80-120 g/L) from
rural Preah Vihear, Cambodia will be recruited to one of three arms to receive LIF, 18 mg
elemental iron, or a placebo. Women with severe anemia will be excluded and referred for
treatment. All three groups will receive nutrition education. Monitoring will be conducted
monthly to measure compliance.
A trained, Khmer-speaking interviewer will meet with the women to explain the details of the
study as per the consent form. Once consent is obtained the trained interviewer will measure
hemoglobin status using a hemocue device to confirm eligibility of the study. If eligible,
the trained interviewer will then administer the baseline questionnaire in the participant's
home.
The questionnaire will collect demographic data, as well as information on current dietary
intake, drinking water treatment, knowledge of iron deficiency anemia, knowledge of malaria,
and perceptions of supplement use.
Participants will have a venous blood sample taken at 0, 6, and 12 months and analyzed for
hemoglobin and multiple biomarkers of iron status (e.g. soluble transferrin receptor,
ferritin, and retinol binding protein (RBP)). Ferritin will be corrected for inflammation
using measures of alpha-1 acid glycoprotein (AGP, g/L) and C-reactive protein (CRP, mg/L)
which are biomarkers of chronic and acute inflammation, respectively.
Genotyping will be conducted to determine the prevalence of hemoglobinopathies among women.
The prevalence of malaria in this cohort will be determined using rapid diagnostic test kits
for P. Falciparum, and P. Vivax at baseline, midline, and endline.
Potential Significance: The LIF has the potential to be a low cost, effective and
simple-to-use product to prevent and reduce iron deficiency anemia in Cambodia.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Completed |
NCT01432717 -
Study of ACE-536 in Healthy Postmenopausal Women
|
Phase 1 | |
Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 |